← Eichor
Study identifier: NCT06509490 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Condition: Safety Issues  ·  Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhaseNA
Planned participants9
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Ning Li, MD  ·  010-87788165  ·  cancergcp@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer hospital Chinese Academy of Medical SciencesBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06509490